All Novo Nordisk A/S articles
-
NewsNovo Nordisk’s Awiqli first FDA-approved once-weekly basal insulin
The type 2 diabetes injection reduces administration frequency from daily to once per week, enhancing convenience for patients.
-
NewsAlzheimer’s Phase III miss signals GLP-1RA combination therapy potential
Novo Nordisk is evaluating oral GLP-1 drug Rybelsus as a potential treatment in early symptomatic Alzheimer’s.
-
NewsCounterfeit diabetes pens identified in EU and UK
Following shortages of the diabetes medicine Ozempic (semaglutide), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have confirmed cases of falsely labelled pre-filled pens at UK and EU wholesalers.